Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Kite registers new Phase 3 trial of anitocabtagene autoleucel in newly diagnosed multiple myelomaOct 29Weekly roundup, 4 itemsanitocabtagene autoleucelaxicabtagene ciloleucelUpdated
Gilead registers two Phase 2 trials: PBC combo study and weekly oral HIV regimenSep 25Weekly roundup, 2 itemsGilead SciencesGS-3242
Gilead reports Q2 2026 results with three FDA approvals, three positive Phase 3 readoutsAug 4Quarterly updateGilead Sciences